Cell Therapeutics' Pixantrone Under NICE Consideration

Biopharmaceutical company Cell Therapeutics, Inc. has announced that the National Institute for Health and Care Excellence (NICE), a non-departmental public body of the Department of Health in the United Kingdom (UK), has issued second draft guidance on Pixurvi (pixantrone) as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma (aggressive B-cell NHL).

An independent Appraisal Committee for NICE got together on Sept. 11, 2013 to weigh the cost effectiveness of pixantrone using Cell Therapeutics' initial patient access scheme that was approved by the Department of Health in July of 2013.

Reassessing evidence

This committee concluded that the patient access scheme failed to overcome the "uncertainties in the evidence for pixantrone's clinical effectiveness" and is requesting that consultees, including CTI, healthcare professionals and members of the public, not comment on the draft guidance via the NICE website. A final Appraisal Committee meeting is scheduled for the middle of November, and at this time CTI is expected to learn whether NICE will consider a so-called enhanced patient access scheme in the UK.

The European Commission (EC) granted conditional marketing authorization in the European Union for pixantrone in May of 2012 as a monotherapy for adult patients with multiply relapsed or refractory aggressive B-cell NHL. Approval was based on the results of the EXTEND (PIX301) pivotal randomized Phase III clinical trial. The drug has therefore been available to patients in eight European countries for more than a year.

Source: CTI

More Articles

More Articles

Secondary cancers are cancers that develop as a result of chemotherapy and/or...

Small lymphocytic lymphoma (SLL), is a type of non-Hodgkin lymphoma characterized by an excess of white blood cells in the...

Lymphoplasmacytic Lymphoma (LPL) is an indolent (slow growing) cancer that affects plasma cells. A plasma cell...

Lymphomas can arise from most any lymphatic tissue (lymph nodes, spleen, thymus, mucosa associated lymphoid...

Treatment for Non-Hodgkin’s Lymphomas (NHL) differs from patient to patient. The regimen used depends on the type of...

Over the years, various classification systems have been used to differentiate lymphoma types including the Rappaport Classification (used until...

Advances in the treatment of Hodgkin's lymphoma have resulted in remarkable survival rates, even for...

The question of what the difference is between leukemia and lymphoma is a commonly asked question. We should start by saying that emerging...

Lymphoma is a cancer of the lymphatic system, causing B-cell or...

As one of two primary categories of lymphatic cancer, Hodgkin's lymphoma (HL) attacks the patient's white...

The diagnosis of a low grade B cell lymphoma is both a specific and a non-specific diagnosis that contains the following components:

What...

Hearing about lymphoma recurrence is about the least-welcome news a patient can hear. But what exactly does it mean?

To begin, lymphoma...

BEAM chemotherapy is an acronym representing a small family of combination chemotherapy regimens that are used chiefly as salvage regimens in the...

This entry looks at a non-Hodgkin's lymphoma called true histiocytic lymphoma (THL), also referred to as diffuse histiocytic lymphoma, and...

The term 'metastatic lymphoma' does not refer to a diagnosis. Unlike many of the subtypes of lymphoma we have...